Niki BioSolutions Enters Strategic Agreement to Provide APOE Genotyping Services for Progressive Medical Research
核心洞察
Niki BioSolutions (搜索), through its subsidiary DiamiR Biosciences (搜索), will provide APOE genotyping services to Progressive Medical Research (PMR) (搜索) for clinical and translational research programs.
APOE genotyping is a key genetic marker with significant implications in Alzheimer's disease (搜索), cardiovascular health, and lipid metabolism studies.
The partnership leverages Niki BioSolutions (搜索)' CAP-accredited and New York State CLEP-approved testing platform to integrate validated genetic data into PMR's clinical trial workflows.
Niki BioSolutions (搜索), Inc., a clinical-stage life sciences company focused on unmet medical needs and high-quality genomic and biomarker testing solutions, announced today that its wholly-owned subsidiary, DiamiR Biosciences (搜索), has entered into an agreement to provide Progressive Medical Research (PMR) (搜索) with Apolipoprotein E (APOE) (搜索) genotyping services. The partnership, announced on July 23, 2026, is designed to support PMR's ongoing clinical and translational research programs by integrating high-quality, validated genetic data directly into clinical trial workflows.
APOE genotyping is widely recognized as one of the key genetic markers with significant clinical implications, particularly in studies related to Alzheimer's disease (搜索), cardiovascular health, and lipid metabolism. The APOE ε4 allele, in particular, is the strongest known genetic risk factor for late-onset Alzheimer's disease, making accurate and reliable genotyping essential for risk stratification and clinical trial design.
Testing Platform and Infrastructure
Under the agreement, PMR will leverage Niki BioSolutions (搜索)' College of American Pathologists (CAP) and New York State Clinical Laboratory Evaluation Program (CLEP) approved testing platform and laboratory infrastructure. These accreditations ensure that the genotyping services meet rigorous quality standards required for clinical research applications. Niki BioSolutions operates through its CLIA-certified, CAP-accredited laboratory, combining proprietary technologies with a commitment to scientific rigor to support precision medicine across multiple therapeutic areas, including brain health and oncology.
Strategic Significance
The collaboration reflects both organizations' shared commitment to advancing precision medicine and generating actionable genetic insights that can inform clinical research and therapeutic development in Alzheimer's disease (搜索). By embedding APOE genotyping into its research programs, PMR gains the ability to stratify patient populations based on genetic risk profiles, a capability increasingly viewed as critical for the success of Alzheimer's clinical trials.
Ian Huen, CEO of Niki BioSolutions (搜索), commented on the agreement: "This agreement reflects our commitment to putting Niki BioSolutions at the forefront of genetic testing for serious disease research. APOE genotyping sits at the intersection of Alzheimer's risk stratification, clinical trial design, and precision medicine, and having a reliable, high-quality testing partner is critical to getting that science right. We are proud to support Premier Medical Research's work and look forward to a collaboration that moves the field forward and, ultimately, improves outcomes for patients."
Financial terms of the agreement have not been disclosed.
Organizational Profiles
Niki BioSolutions (搜索) collaborates with leading academic centers, disease foundations, and biopharma companies, positioning itself at the intersection of diagnostic testing and therapeutic development. Progressive Medical Research is a clinical and translational research organization dedicated to advancing medical science through rigorous, evidence-based investigation, partnering with industry, academic, and healthcare stakeholders to accelerate the development of innovative diagnostics, therapeutics, and care strategies.